|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The frequency of MGMT promoter hypermethylation in the GC group (32.97%) was significantly higher than those in the control group (18.00%) (OR = 2.83, CI = 1.93-4.15, P < .05).
|
28445279 |
2017 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
|
28903131 |
2017 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Hence, we conducted a systematic meta-analysis to explore the potential correlation of MGMT promoter methylation with gastric cancer and its clinicopathologic characteristics.
|
28384044 |
2017 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of MGMT expression induced increases in GC cell metastasis and invasion potential in vitro and in vivo.
|
27291049 |
2016 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that tumor suppressor genes hypermethylation, represented by MGMT, positively correlated with CagA in clinical specimens, gastric tissues from HP infected C57 mice and GC cell lines transfected by CagA or treated by HP infection.
|
26848521 |
2016 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Atomic Insight into the Altered O6-Methylguanine-DNA Methyltransferase Protein Architecture in Gastric Cancer.
|
26011121 |
2015 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Promoter hypermethylation of the MGMT gene has been observed in various cancers, including gastric cancer.
|
25008999 |
2014 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we found that aberrant hypermethylation of MGMT could be a predictive biomarker for detecting gastric cancer.
|
24938706 |
2014 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A great number of genes with promoter methylation have been observed in gastric cancer (GC), among which p16INK4A (p16), Mut L homologue 1 (MLH1), Epithelial-cadherin (E-cadherin), Runt-related transcription factor 3 (RUNX3), adenomatous polyposis coli (APC), O(6)-methylguanine-DNA methyltransferase (MGMT), Ras association domain family 1A (RASSF1A) and Death-associated protein kinase (DAPK) have been extensively studied.
|
22936446 |
2012 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphic variants of base excision repair (APE1-D148E, XRCC1-R194W, XRCC1-R399Q and OGG1-S326C), nucleotide excision repair (XPC-PAT, XPA-23G>A, ERCC1-19007T>C and XPD-L751Q), recombination (XRCC3-T241M) and alkylation damage reversal (MGMT-L84F) were tested for their potential role in the development of GC by using logistic regression models.
|
20817763 |
2010 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation status of the MGMT gene was examined in primary carcinomas and the corresponding normal tissues derived from 38 patients with gastric cancer using quantitative methylation-specific PCR (qMSP) and the correlation between the methylation status and the clinicopathological findings was evaluated.
|
20044616 |
2009 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed DNA methylation of 12 tumor-related genes (hMLH1, MGMT, p16(INK4a), CDH1, RAR-beta, HLTF, RIZ1, TM, FLNc, LOX, HRASLS, HAND1) in 75 samples of GC from 75 patients, 25 samples of corresponding nonneoplastic mucosa from 25 patients, and 10 samples of normal gastric mucosa from 10 healthy young individuals by methylation-specific polymerase chain reaction (PCR) and bisulfite PCR.
|
16475210 |
2006 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To clarify the clinical significance of TSG expression in gastric carcinoma, the expression of various TSG candidates (p53, E-cadherin, FHIT, smad4, rb, VHL, PTEN, MGMT, p16, and KAI1), as well as other proteins (bcl-2, MUC1, MUC2, MUC5AC, MUC6, CEA, CD44, beta-catenin, C-erbB2, and cyclin B2), was evaluated immunohistochemically in 329 consecutive gastric carcinomas using the tissue array method.
|
12692839 |
2003 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For determination of association between DNA methylation pattern or histological type and CIMP status in gastric carcinoma, CpG islands in the promoters of hMLH1 and CDH1 genes, CpG islands overlapping exon 1 of MGMT and p16(INK4a) genes, and a non-CpG island in exon 1 of the RAR-beta gene were studied.
|
14556664 |
2003 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT-promoter methylation in patients with gastric carcinoma was associated significantly with point mutations of K-ras at codons 12 and 13, lymph node invasion, tumor stage, and disease free survival.
|
11753949 |
2001 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma.
|
11519041 |
2001 |